Hemab Therapeutics Holdings COAG
NASDAQ COAG
$40.86 +1.48 (+3.76%)
At close: Nov 13, 2026 · 4:00 PM EST

Hemab Therapeutics Holdings (COAG) Enterprise Value (2026)

Updated

Hemab Therapeutics Holdings (COAG) reported Enterprise Value of $1.01 billion for Q3 2026, up 55.9% from the prior quarter.

Analysis

Hemab Therapeutics Holdings (COAG) Enterprise Value (2026) Analysis & Trends

Over the twelve months ended Sep 30, 2026, Hemab Therapeutics Holdings' Enterprise Value came in at $204.46 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn
10 Hemab Therapeutics Holdings 1.91 Bn 672.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1.01 Bn
Jun 30, 2026 648.53 Mn
API Access

Hemab Therapeutics Holdings Enterprise Value API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=enterprise-value&ticker=COAG&period=max&api_key=YOUR_API_KEY